Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15999467 | 0.89 | HTR2C (0.42) | HTR2CSRD5A1HRH1HTR6HTR2A | |
| SCHEMBL7140355 | 0.89 | HTR2C (0.42) | HTR2CSRD5A1HRH1HTR6HTR2A | |
| SCHEMBL12951637 | 0.89 | HTR2C (0.38) | HTR2CSRD5A1HRH1HTR6HTR2A | |
| SCHEMBL21913053 | 0.82 | HRH1 (0.48) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL11350931 | 0.82 | HRH1 (0.48) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL12938774 | 0.82 | SRD5A1 (0.45) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL11349641 | 0.82 | HRH1 (0.48) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL20385076 | 0.81 | HRH1 (0.47) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL25557913 | 0.81 | HRH1 (0.47) | SRD5A1HRH1HTR6GPR3 | |
| SCHEMBL12938772 | 0.81 | HRH1 (0.47) | SRD5A1HRH1HTR6GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |